A skin condition improving agent containing Staphylococcus hominis as an active ingredient

Abstract

To provide a novel technique that achieves prevention or improvement of skin conditions based on an increased number of conspicuous pores, an increased amount of melanin, or an increased number of wrinkles.SOLUTION: A skin condition improver contains Staphylococcus hominis as an active ingredient.SELECTED DRAWING: None

Description

[Technical field]

[0001] The present invention relates to a skin condition improving agent containing Staphylococcus hominis as an active ingredient. [Background technology]

[0002] In recent years, cosmetic compositions containing, as active ingredients, bacterial cells having beneficial effects on the human body have been proposed (for example, Patent Document 1).

[0003] For example, Patent Document 2 discloses the use of Staphylococcus hominis as an active ingredient in the treatment of atopic dermatitis. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] Japanese Patent Application Publication No. 09-020638 [Patent Document 2] Special Publication No. 2018-515488 Summary of the Invention [Problem to be solved by the invention]

[0005] In view of the above-mentioned prior art, an objective of the present invention is to provide a novel technology that realizes the prevention or improvement of skin conditions based on any one of an increase in the number of noticeable pores, an increase in the amount of melanin, and an increase in the number of wrinkles. [Means for solving the problem]

[0006] As a result of extensive research efforts, the inventors have discovered that Staphylococcus hominis has the effect of preventing or improving skin conditions caused by an increase in the number of noticeable pores, an increase in the amount of melanin, or an increase in the number of wrinkles, and have completed the present invention.

[0007] In other words, the present invention, which solves the above-mentioned problems, is a skin condition improving agent containing Staphylococcus hominis as an active ingredient, for preventing or improving skin conditions caused by an increase in the number of noticeable pores, an increase in the amount of melanin, or an increase in the number of wrinkles.

[0008] In a preferred embodiment of the present invention, the skin condition is one or more selected from rough skin, increased sebum production, intractable acne, seborrheic skin, age spots, dull skin, pigmentation, post-inflammatory pigmentation, solar lentigo, wrinkles, decreased dermal elasticity due to solar elastosis, decreased dermal elasticity due to Ehles-Danlos syndrome, decreased dermal elasticity due to Marfan syndrome, decreased dermal elasticity due to pseudoxanthoma elasticum, decreased dermal elasticity due to dysplasia, and decreased dermal elasticity due to progeria.

[0009] In a preferred embodiment of the invention, the active ingredient is Staphylococcus hominis strain GTC485.

[0010] The present invention is also preferably in the form of a composition for external use on the skin.

[0011] The present invention is preferably in the form of a pharmaceutical product. Effect of the Invention

[0012] According to the present invention, a novel technology can be provided that has the effect of preventing or improving skin conditions caused by an increase in the number of noticeable pores, an increase in the amount of melanin, or an increase in the number of wrinkles. [Brief description of the drawings]

[0013] [Figure 1] FIG. 1 is a diagram showing the results of Test Example 1. [Diagram 2] FIG. 1 shows the results of Test Example 2. [Diagram 3] FIG. 13 is a graph showing the results of Test Example 3. [Figure 4] FIG. 13 is a diagram showing the results of Test Example 4. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] Next, preferred embodiments of the present invention will be described in detail. However, the present invention is not limited to the following embodiments and can be freely modified within the scope of the present invention.

[0015] The active ingredient Staphylococcus hominis in the present invention can be isolated from samples collected from various environments reported to be habitats of Staphylococcus hominis, or a commercially available strain or a deposited strain can be used.

[0016] As the deposited strain, Staphylococcus hominis GTC485 strain can be used.

[0017] The Staphylococcus hominis GTC485 strain has been deposited at the Center for Conservation of Microbial Genetic Resources (GCMR, Gifu University Research Promotion and Social Collaboration Organization, Gifu University School of Medicine, postal code: 501-1194, address: 1-1 Yanagido, Gifu City) and is publicly available.

[0018] The Staphylococcus hominis GTC485 strain has been assigned List No. 238 by the Japanese Society for Bacteriology (Postal Code: 170-0003, Address: Komagome TS Building, 1-43-9 Komagome, Toshima-ku, Tokyo Oral Health Association (Foundation)) and can also be obtained through the Japanese Society for Bacteriology (see "Appendix 1: List of Bacteriological Educational Strains by Institution - Japanese Society for Bacteriology," [pdf], Japanese Society for Bacteriology, Internet, URL: http: / / jsbac.org / material / strain_kikan.pdf).

[0019] The strain is also available from the American Type Culture Collection (ATCC) under accession number ATCC 27844.

[0020] Staphylococcus hominis GTC485 strain can be cultured by a conventional method, for example, using SCD agar medium at a temperature of 30 to 37°C (preferably 37°C), pH 5 to 9 (preferably pH 7.0), and aerobic conditions.

[0021] Also, in the present invention, a culture of Staphylococcus hominis can be used.

[0022] Here, the culture refers to a composition containing a metabolic product of Staphylococcus hominis obtained by culturing by the above-mentioned method, etc. That is, as the culture, a composition containing a metabolic product, medium components, and cells of Staphylococcus hominis can be used as it is, or a fraction containing a metabolic product of Staphylococcus hominis can be separated and purified from the composition by a method such as filtration, centrifugation, extraction, etc. and used. The culture may also be one that has been subjected to a concentration and drying process.

[0023] Staphylococcus hominis, the active ingredient of the present invention, has the effect of preventing or improving skin conditions caused by an increase in the number of noticeable pores, an increase in the amount of melanin, or an increase in the number of wrinkles.

[0024] In this specification, the concept of "prevention" includes reducing the risk of developing a disease, and the concept of "improvement" includes both treatment and alleviation of symptoms.

[0025] Here, examples of skin conditions caused by an increase in the number of noticeable pores include rough skin and increased sebum production. Staphylococcus hominis is effective in preventing or improving the above-mentioned skin conditions. More specifically, Staphylococcus hominis is effective in improving rough skin and suppressing an increase in sebum production.

[0026] Here, intractable acne (acne conglobata, pyoderma) is a type of chronic inflammatory disease occurring mainly in pores, and is a skin condition caused by an increase in the number of noticeable pores. Therefore, intractable acne (acne conglobata, pyoderma) is a skin condition that can be prevented or improved by inhibiting or reducing the increase in the number of noticeable pores. That is, Staphylococcus hominis can also be used as an agent for preventing or improving scars in intractable acne (acne conglobata, pyoderma).

[0027] Seborrheic skin is a type of inflammation that is seen mainly in areas with high lipid secretion (pores), and is a skin condition caused by an increase in the number of noticeable pores. Therefore, seborrheic skin is a skin condition that can be prevented or improved by inhibiting or reducing the increase in the number of noticeable pores. From the above, Staphylococcus hominis can also be used as an agent for preventing or improving seborrheic skin.

[0028] In addition, skin conditions caused by increased amounts of melanin include age spots, dullness, pigmentation, post-inflammatory pigmentation, and solar pigmentation. Staphylococcus hominis is effective in preventing or improving the above-mentioned skin conditions. More specifically, Staphylococcus hominis is effective in reducing and / or inhibiting spots, reducing and / or inhibiting dullness, reducing and / or inhibiting hyperpigmentation, treating post-inflammatory hyperpigmentation, and treating solar pigmentation.

[0029] Furthermore, an example of a skin condition caused by an increase in the number of wrinkles is wrinkles. Staphylococcus hominis is effective in preventing or improving the above-mentioned skin conditions. More specifically, Staphylococcus hominis is effective in reducing and / or inhibiting wrinkles.

[0030] Here, actinic elastosis, Ehles-Danlos syndrome, Marfan syndrome, pseudoxanthoma elasticum, dysplasia cutis, and progeria are diseases in which reduced elasticity of the dermis occurs as a symptom, and the reduced elasticity of the dermis causes an increase in the number of wrinkles. Therefore, an active ingredient that exhibits the effect of inhibiting the increase and / or reducing the number of wrinkles can also be used as an agent for preventing or improving decreased dermal elasticity due to actinic elastosis, decreased dermal elasticity due to Ehles-Danlos syndrome, decreased dermal elasticity due to Marfan syndrome, decreased dermal elasticity due to pseudoxanthoma elasticum, decreased dermal elasticity due to dysplasia, and decreased dermal elasticity due to premature aging. Based on the above, Staphylococcus hominis can also be used as an agent to prevent or improve decreased dermal elasticity due to actinic elastosis, decreased dermal elasticity due to Ehles-Danlos syndrome, decreased dermal elasticity due to Marfan syndrome, decreased dermal elasticity due to pseudoxanthoma elasticum, decreased dermal elasticity due to dysplasia, and decreased dermal elasticity due to premature aging.

[0031] The skin condition improving agent of the present invention can be applied to mammals including humans. The form of application may be selected from either a composition for external use on the skin (application onto the skin) or a composition for oral administration (oral administration) depending on the symptoms of the patient.

[0032] Examples of skin external compositions include cosmetics, quasi-drugs, and skin external medicines. Since Staphylococcus hominis, the active ingredient of the present invention, has the effect of preventing or improving skin conditions resulting from an increase in the number of noticeable pores, an increase in the amount of melanin, or an increase in the number of wrinkles, it is preferable for it to be in the form of a cosmetic preparation that can be used continuously. Among others, the present invention is preferably applied to lotions, beauty essences, milky lotions, creams, gels and sun care products.

[0033] In addition, since Staphylococcus hominis, the active ingredient of the present invention, has the effect of preventing or improving skin conditions caused by an increase in the number of noticeable pores, an increase in the amount of melanin, or an increase in the number of wrinkles, it is also preferable to formulate it into a medicine.

[0034] The amount of Staphylococcus hominis cells in the composition for external use on the skin of the present invention varies depending on the formulation of the composition for external use on the skin. However, it is preferably 0.5×10 9 CFU or more, preferably 0.8×10 9 It can be designed to deliver an amount of CFU or more to the skin. The amount of Staphylococcus hominis cells in the composition for external use on the skin of the present invention is preferably 2.0×10 9 CFU or less, preferably 1.5 x 10 9 It can be designed so that the amount applied to the skin is less than CFU.

[0035] The amount of Staphylococcus hominis cells in the composition for external use on the skin of the present invention varies depending on the formulation of the composition for external use on the skin, but is preferably 3×10 9 CFU / mL or more, preferably 4×10 9 CFU / mL or higher can be used as a guideline. The amount of Staphylococcus hominis cells in the composition for external use on skin of the present invention is preferably 8×10 9 CFU / mL or less, preferably 6 x 10 9 CFU / mL or less can be used as a guideline.

[0036] The topical skin composition of the present invention can be applied to mammals, including humans, once a week or several times a week, and it is preferable to apply the skin condition improving agent of the present invention continuously.

[0037] When the topical composition for skin of the present invention is applied continuously, the application period of the topical composition for skin of the present invention is preferably 2 weeks or more, more preferably 3 weeks or more, and even more preferably 4 weeks or more. Furthermore, when the topical composition for skin of the present invention is applied continuously for the above-mentioned period, the frequency of application can be once or more, preferably twice or more, per week.

[0038] When the composition is provided in the form of a skin external composition, its composition is not particularly limited, and it can contain any optional ingredient that is usually used, as long as it does not impair the effect of the present invention.Such optional ingredients include, for example, oils and waxes such as macadamia nut oil, avocado oil, corn oil, olive oil, rapeseed oil, sesame oil, castor oil, safflower oil, cottonseed oil, jojoba oil, coconut oil, palm oil, liquid lanolin, hydrogenated coconut oil, hydrogenated oil, Japan wax, hydrogenated castor oil, beeswax, candelilla wax, carnauba wax, ivotaro wax, lanolin, reduced lanolin, hard lanolin, and jojoba wax; liquid paraffin, squalane, pristane, ozokerite, paraffin, ceresin, petrolatum, micelle, and the like. Hydrocarbons such as locrystalline wax; higher fatty acids such as oleic acid, isostearic acid, lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, and undecylenic acid; higher alcohols such as cetyl alcohol, stearyl alcohol, isostearyl alcohol, behenyl alcohol, octyldodecanol, myristyl alcohol, and cetostearyl alcohol; cetyl isooctanoate, isopropyl myristate, hexyldecyl isostearate, diisopropyl adipate, sebacic acid, and the like; synthetic ester oils such as di-2-ethylhexyl phosphate, cetyl lactate, diisostearyl malate, ethylene glycol di-2-ethylhexanoate, neopentyl glycol dicaprate, glycerin di-2-heptylundecanoate, glycerin tri-2-ethylhexanoate, trimethylolpropane tri-2-ethylhexanoate, trimethylolpropane triisostearate, pentane erythritol tetra-2-ethylhexanoate, and other oils; fatty acid soaps (sodium laurate, sodium palmitate, etc.); anionic surfactants such as potassium lauryl sulfate, alkyl sulfate triethanolamine ether; cationic surfactants such as stearyltrimethylammonium chloride, benzalkonium chloride, laurylamine oxide; amphoteric surfactants such as imidazoline-based amphoteric surfactants (2-cocoyl-2-imidazolinium hydroxide-1-carboxyethyloxy disodium salt, etc.), betaine-based surfactants (alkyl betaine, amido betaine, sulfo betaine, etc.), and acyl methyl taurine;Sorbitan fatty acid esters (sorbitan monostearate, sorbitan sesquioleate, etc.), glycerin fatty acids (glycerin monostearate, etc.), propylene glycol fatty acid esters (propylene glycol monostearate, etc.), hydrogenated castor oil derivatives, glycerin alkyl ethers, POE sorbitan fatty acid esters (POE sorbitan monooleate, polyoxyethylene sorbitan monostearate, etc.), POE sorbitol fatty acid esters (POE-sorbitol monolaurate, etc.), POE glycerin fatty acid esters (POE-glycerin monoisostearate, etc.), POE fatty acid esters (polyethylene glycol monooleate, POE distearate, etc.), POE alkyl ethers (POE 2-octyldodecyl ether, etc.), POE alkyl phenyl ethers (POE nonylphenyl ether, etc.), Pluronic types, POE·PO Preferred examples of the surfactants include nonionic surfactants such as P alkyl ethers (POE·POP 2-decyltetradecyl ether, etc.), tetronics, POE castor oil·hydrogenated castor oil derivatives (POE castor oil, POE hydrogenated castor oil, etc.), sucrose fatty acid esters, and alkyl glucosides; polyhydric alcohols such as polyethylene glycol, glycerin, erythritol, sorbitol, xylitol, maltitol, propylene glycol, and 2,4-hexanediol; moisturizing ingredients such as sodium pyrrolidone carboxylate, lactic acid, and sodium lactate; para-aminobenzoic acid-based ultraviolet absorbers; anthranilic acid-based ultraviolet absorbers; salicylic acid-based ultraviolet absorbers; cinnamic acid-based ultraviolet absorbers; benzophenone-based ultraviolet absorbers; sugar-based ultraviolet absorbers; and ultraviolet absorbers such as 2-(2'-hydroxy-5'-t-octylphenyl)benzotriazole and 4-methoxy-4'-t-butyldibenzoylmethane.

[0039] Oral compositions also include those in the form of food or medicine.

[0040] Suitable examples of foods include general foods such as sweets, bread, and noodles, and food groups for the purpose of promoting health (e.g., foods for specified health uses) in the form of drink preparations, granules, powders, capsules, or tablets. Suitable examples of pharmaceuticals include orally administered pharmaceuticals in the form of granules, powders, capsules, or tablets.

[0041] These foods and medicines may contain acceptable optional ingredients. In the case of foods, suitable optional ingredients include seasoning ingredients such as salt, sugar, monosodium glutamate, sodium inosinate, and vinegar, coloring ingredients, odor-correcting ingredients such as flavors, thickeners, emulsifiers / dispersants, preservatives, stabilizers, and various vitamins, in addition to general food ingredients, and in the case of foods and medicines intended for health promotion, suitable examples include excipients such as crystalline cellulose and lactose, binders such as gum arabic and hydroxypropyl cellulose, disintegrants such as croscarmellose sodium and starch, lubricants such as magnesium stearate, flavorings, odorants, colorants, and various vitamins. The composition of the present invention can be produced by processing these ingredients according to a conventional method. EXAMPLES

[0042] The association between the following skin condition parameters and Staphylococcus hominis (S. hominis) was investigated: Unless otherwise specified, the bacterial counts listed below are the number of reads and represent the abundance of Staphylococcus hominis (S. hominis).

[0043] <1> Cultivation of strains In this example, Staphylococcus hominis GTC485 strain (hereinafter, also simply referred to as S. hominis) was used as Staphylococcus hominis. Here, the Staphylococcus hominis GTC485 strain was purchased through the Japanese Society for Bacteriology (Postal Code: 170-0003, Address: Komagome TS Building, 1-43-9 Komagome, Toshima-ku, Tokyo, Japan (Oral Health Association).

[0044] The obtained S. hominis was cultured in BBL-Tripticase Soybean Agar medium (Becton Dickinson, ND, USA) at pH 7.3 under aerobic conditions at 37°C. The cultured cells were harvested, suspended in a 10% skim milk solution, and then vacuum-lyophilized using the L-drying method to obtain S. hominis lyophilized material (approximately 10 11 The freeze-dried S. hominis thus produced was used in the following tests.

[0045] <2> Test method, measurement of S. hominis amount and skin condition <2-1> Test method (1) Subjects The subjects were 11 healthy Japanese women in their 30s who did not have any diseases such as atopic dermatitis.

[0046] (2) Test method (2-1) Manufacture of S. hominis-containing cosmetics (Examples) and S. hominis-free cosmetics (Comparative examples, placebo cosmetics) The above freeze-dried S. hominis was suspended in 10 mL of distilled water to form a suspension (S. hominis content: approximately 10 10 CFU / mL) were prepared. 1 mL of the prepared suspension was mixed with 1 mL of lotion (containing polyethylene glycol, dipropylene glycol, glycerin, diglycerin, potassium hydroxide, and water) to prepare a cosmetic containing S. hominis (Example, S. hominis content: approximately 5 × 10 9 CFU / mL) were produced. In addition, a cosmetic preparation not containing S. hominis (comparative example, placebo cosmetic preparation) was produced in the same manner as the cosmetic preparation containing S. hominis, except that freeze-dried skim milk not containing S. hominis was used instead of the freeze-dried S. hominis.

[0047] (2-2) Application of cosmetics The subjects applied 0.2 mL of the cosmetic product containing S. hominis (Example) to one of the left and right cheeks, and 0.2 mL of the cosmetic product not containing S. hominis (Comparative Example, placebo cosmetic product) to the other cheek. 9 CFU) was applied twice a week for one month. One month after starting application of the cosmetic preparation, the skin condition and amount of S. hominis on the cheeks were measured using the following methods.

[0048] <2-2> Measurement of S. hominis quantity and skin condition (1) Test Example 1: Measurement and evaluation of the amount of S. hominis in the cheek The amount of S. hominis on each cheek was measured using the following method before the start of cosmetic application, during the cosmetic application period, and at the end of the cosmetic application test (one month after the start of cosmetic application).

[0049] Bacterial flora was collected from the cheeks of female subjects using a sticker or cotton swab (Swab method). DNA was then extracted from the collected bacterial flora, and S. hominis was analyzed by OTU (Operational Taxonomic Unit) analysis. The amount of S. hominis was measured by counting the number of reads belonging to each OTU.

[0050] The amount of S. hominis for each subject at the time of each cosmetic application test was calculated by setting the number of S. hominis leads before application of the cosmetic as 1, and calculating the ratio of the number of leads one week after application, two weeks after application, three weeks after application, and one month after application. The results were expressed as the mean ± standard error (se) for each subject (N = 11). Statistical analysis was performed based on two-way analysis of variance (*P < 0.05).

[0051] (2) Test Example 2: Measurement and evaluation of the number of noticeable pores Before the start of cosmetic application and at the end of the cosmetic application test (one month after the start of cosmetic application), the number of noticeable pores on the cheeks was evaluated using the following method.

[0052] First, a skin image was taken using a skin image analysis counseling system (Canfield, VISIA-EVOLUTION), and the number of noticeable pores of the subject was counted by image analysis. The difference between the number of pores measured at the end of the cosmetic application test and the number of pores before the start of cosmetic application was calculated, and this was taken as the change in the number of noticeable pores (Δnumber of noticeable pores).

[0053] Here, a larger value of the change in the number of noticeable pores (Δnumber of noticeable pores) indicates a greater decrease in the number of noticeable pores. The results were expressed as the mean ± standard error (se) of the change in the number of noticeable pores for each subject (N=11) based on the Wilcoxon signed rank test (*P<0.05).

[0054] (3) Test Example 3: Measurement and evaluation of melanin index Before the start of cosmetic application and at the end of the cosmetic application test (one month after the start of cosmetic application), the melanin index in the cheeks was evaluated by the following method.

[0055] First, the absorbance (A) was measured using a spectrophotometer (Konica Minolta Sensing Co., Ltd., CM2600d), and then the melanin index (MI) was calculated using the formula (MI = A 640 -A 670 The melanin index of the subjects was measured by calculating the melanin index using the formula (F(x,y)) and the Feather's formula. The difference between the measured melanin index at the end of the cosmetic application test and the melanin index before the start of cosmetic application was calculated and used as the change in melanin index (Δmelanin index).

[0056] Here, a larger value of the change in melanin index (Δmelanin index) indicates a greater decrease in the melanin index. The results were expressed as the mean ± standard error (se) for each subject (N = 11) based on the Wilcoxon signed rank test (*P < 0.05).

[0057] (4) Test Example 4: Measurement and evaluation of the number of wrinkles Before the start of cosmetic application and at the end of the cosmetic application test (one month after the start of cosmetic application), the number of noticeable wrinkles on the cheeks was evaluated using the following method.

[0058] First, a skin image was taken using a skin image analysis counseling system (VISIA-EVOLUTION, manufactured by Canfield) and the number of wrinkles of the subject was counted by image analysis. The difference between the number of wrinkles measured at the end of the cosmetic application test and the number of wrinkles before the start of cosmetic application was calculated and used as the change in the number of wrinkles (Δnumber of wrinkles).

[0059] Here, a larger value of the change in the number of wrinkles (Δnumber of wrinkles) indicates a greater reduction in the number of wrinkles. In addition, the results were expressed as the mean ± standard error (se) of the change in the number of wrinkles (Δnumber of wrinkles) for each subject (N=11) based on the Wilcoxon signed rank test (*P<0.05).

[0060] <2-3>Result The results are shown in Tables 1 and 2 and FIGS.

[0061] [Table 1]

[0062] [Table 2]

[0063] As shown in Table 1 and Figure 1, it was found that the amount of S. hominis increased in subjects who continuously used cosmetics containing S. hominis.

[0064] In addition, as shown in Table 2 and Figure 2, the change in the number of noticeable pores (Δ number of noticeable pores) was greater on the cheeks of subjects who had continuously used cosmetics containing S. hominis compared to the cheeks of subjects who had used cosmetics not containing S. hominis. In other words, it was found that the number of pores was reduced on the cheeks of subjects who had continuously used cosmetics containing S. hominis compared to the cheeks of subjects who had used cosmetics not containing S. hominis.

[0065] From the above, it was found that S. hominis has the effect of preventing or improving skin conditions caused by an increase in the number of noticeable pores.

[0066] In addition, as shown in Table 2 and Figure 3, the subjects who continuously used cosmetics containing S. hominis had a larger change in melanin index (Δ melanin index) compared to the cheeks of subjects who used cosmetics not containing S. hominis. In other words, it was found that the melanin index of the cheeks of subjects who continuously used cosmetics containing S. hominis was reduced compared to the cheeks of subjects who used cosmetics not containing S. hominis.

[0067] From the above, it was found that S. hominis has the effect of preventing or improving skin conditions caused by increased melanin levels.

[0068] As shown in Table 2 and Figure 4, the change in the number of wrinkles (Δ number of wrinkles) was greater on the cheeks of subjects who had continuously used cosmetics containing S. hominis compared to the cheeks of subjects who had used cosmetics not containing S. hominis. In other words, it was found that the number of wrinkles was reduced on the cheeks of subjects who had continuously used cosmetics containing S. hominis compared to the cheeks of subjects who had used cosmetics not containing S. hominis.

[0069] From the above, it was found that S. hominis has the effect of preventing or improving skin conditions caused by an increase in the number of wrinkles.

[0070] <Cosmetics: Formulation examples> (1) Preparation of the blended bacterial material The freeze-dried product of S. hominis was used as the bacterial cell in the following formulation examples. In the formulation examples, Staphylococcus hominis GTC485 strain was used as S. hominis.

[0071] (2) Preparation of lotion A skin lotion, which is a skin topical composition of the present invention, was prepared according to the formulation in Table 3. First, component A shown in Table 3 was mixed at room temperature and component B was heated to 60° C. Then, component B was gradually added to component A while stirring, and the mixture was cooled with stirring to obtain a skin lotion.

[0072] [Table 3]

[0073] (3) Preparation of UV cream An O / W UV cream, which is a skin topical composition of the present invention, was prepared according to the formulation in Table 4. First, ingredients A and B shown in Table 4 were heated to 80°C and mixed together. Then, B was gradually added to A while stirring, and the mixture was cooled with stirring to obtain an O / W UV cream.

[0074] [Table 4]

[0075] <Medicine: Prescription Examples> (1) Preparation of the blended bacterial material The concentrated solution of S. hominis cells was used as the cells in the following formulation examples. In the formulation examples, the Staphylococcus hominis GTC485 strain was used as S. hominis.

[0076] (2) Ointment According to the formulation in Table 5, each component was mixed to prepare an ointment, which is a pharmaceutical composition of the present invention.

[0077] [Table 5] [Industrial Applicability]

[0078] The present invention can be applied to cosmetics, quasi-drugs, and pharmaceuticals.

Claims

1. The product contains Staphylococcus hominis GTC485 strain as an active ingredient and is used to prevent or improve skin conditions caused by an increase in the number of noticeable pores, an increase in the amount of melanin, or an increase in the number of wrinkles. The skin condition improving agent is one or more selected from an increase in sebum amount, seborrheic skin, age spots, dullness, pigmentation, post-inflammatory pigmentation, solar pigmentation, and wrinkles.

2. A skin condition improving agent according to claim 1 as an active ingredient, It is used to prevent or improve skin conditions based on any of an increase in the number of noticeable pores, an increase in the amount of melanin, and an increase in the number of wrinkles, The skin condition is one or more selected from the group consisting of increased sebum, seborrheic skin, age spots, dullness, pigmentation, post-inflammatory pigmentation, solar pigmentation, and wrinkles. A composition for external application to the skin for improving skin condition.

3. The composition for external application to skin according to claim 2 , which is a cosmetic preparation.

4. The composition for external application to skin according to claim 2, which is a pharmaceutical product.

Images